{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:04:42Z","timestamp":1788285882354,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2018YFA0902803"],"award-info":[{"award-number":["2018YFA0902803"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81825016"],"award-info":[{"award-number":["81825016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Guangzhou","award":["201604020156"],"award-info":[{"award-number":["201604020156"]}]},{"DOI":"10.13039\/501100009334","name":"Pearl River S&T Nova Program of Guangzhou","doi-asserted-by":"crossref","award":["201806010024"],"award-info":[{"award-number":["201806010024"]}],"id":[{"id":"10.13039\/501100009334","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundamental Research Funds for Young Teachers in the Higher Education Institutions of China","award":["19ykpy116"],"award-info":[{"award-number":["19ykpy116"]}]},{"DOI":"10.13039\/501100013183","name":"Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University","doi-asserted-by":"crossref","award":["KLB09001"],"award-info":[{"award-number":["KLB09001"]}],"id":[{"id":"10.13039\/501100013183","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology","award":["013-163"],"award-info":[{"award-number":["013-163"]}]},{"name":"Key Science Research Projects of Gannan Medical University in 2018","award":["ZD201835"],"award-info":[{"award-number":["ZD201835"]}]},{"name":"Science and Technology Plan Project of Jiangxi Provincial Health Committee","award":["20204519"],"award-info":[{"award-number":["20204519"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00262-021-03063-7","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T06:02:28Z","timestamp":1635660148000},"page":"1507-1517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model"],"prefix":"10.1007","volume":"71","author":[{"given":"Bo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-2347","authenticated-orcid":false,"given":"Zhihua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2602-4345","authenticated-orcid":false,"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"key":"3063_CR1","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","volume":"353","author":"AB Alexandroff","year":"1999","unstructured":"Alexandroff AB, Jackson AM, O\u2019Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689\u20131694. https:\/\/doi.org\/10.1016\/S0140-6736(98)07422-4","journal-title":"Lancet"},{"key":"3063_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati C, Ingersoll MA (2018) Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 15:615\u2013625. https:\/\/doi.org\/10.1038\/s41585-018-0055-4","journal-title":"Nat Rev Urol"},{"key":"3063_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comperat EM et al (2019) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In situ) - 2019 update. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016","journal-title":"Eur Urol"},{"key":"3063_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03032-0","author":"M Kobayashi","year":"2021","unstructured":"Kobayashi M, Fujiyama N, Tanegashima T et al (2021) Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-021-03032-0","journal-title":"Cancer Immunol Immunother"},{"key":"3063_CR5","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D et al (2017) BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol 14:244\u2013255. https:\/\/doi.org\/10.1038\/nrurol.2017.16","journal-title":"Nat Rev Urol"},{"key":"3063_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates M, Matoso A, Choi W et al (2020) Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res 26:882\u2013891. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1920","journal-title":"Clin Cancer Res"},{"key":"3063_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","volume":"11","author":"CJ Lim","year":"2020","unstructured":"Lim CJ, Nguyen PHD, Wasser M et al (2020) Immunological hallmarks for clinical response to BCG in bladder cancer. Front Immunol 11:615091. https:\/\/doi.org\/10.3389\/fimmu.2020.615091","journal-title":"Front Immunol"},{"key":"3063_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","volume":"75","author":"R Li","year":"2019","unstructured":"Li R, Tabayoyong WB, Guo CC, Gonzalez GMN, Navai N, Grossman HB, Dinney CP, Kamat AM (2019) Prognostic implication of the United States food and drug administration-defined BCG-unresponsive disease. Eur Urol 75:8\u201310. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.028","journal-title":"Eur Urol"},{"issue":"253\u2013267","key":"3063_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.07.006","volume":"32","author":"D Saha","year":"2017","unstructured":"Saha D, Martuza RL, Rabkin SD (2017) Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. Cancer Cell 32(253\u2013267):e255. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.006","journal-title":"Cancer Cell"},{"key":"3063_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euf.2015.03.003","volume":"2","author":"E Noguera-Ortega","year":"2016","unstructured":"Noguera-Ortega E, Secanella-Fandos S, Erana H, Gasion J, Rabanal RM, Luquin M, Torrents E, Julian E (2016) Nonpathogenic mycobacterium brumae inhibits bladder cancer growth In vitro, Ex vivo, and In vivo. Eur Urol Focus 2:67\u201376. https:\/\/doi.org\/10.1016\/j.euf.2015.03.003","journal-title":"Eur Urol Focus"},{"key":"3063_CR11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/jcb.22241","volume":"108","author":"ZB Liu","year":"2009","unstructured":"Liu ZB, Hou YF, Min D, Di GH, Wu J, Shen ZZ, Shao ZM (2009) PA-MSHA inhibits proliferation and induces apoptosis through the up-regulation and activation of caspases in the human breast cancer cell lines. J Cell Biochem 108:195\u2013206. https:\/\/doi.org\/10.1002\/jcb.22241","journal-title":"J Cell Biochem"},{"key":"3063_CR12","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/onc.2010.70","volume":"29","author":"ZB Liu","year":"2010","unstructured":"Liu ZB, Hou YF, Zhu J et al (2010) Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner. Oncogene 29:2996\u20133009. https:\/\/doi.org\/10.1038\/onc.2010.70","journal-title":"Oncogene"},{"key":"3063_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1124\/jpet.113.212316","volume":"349","author":"M Zhang","year":"2014","unstructured":"Zhang M, Luo F, Zhang Y, Wang L, Lin W, Yang M, Hu D, Wu X, Chu Y (2014) Pseudomonas aeruginosa mannose-sensitive hemagglutinin promotes T-cell response via toll-like receptor 4-mediated dendritic cells to slow tumor progression in mice. J Pharmacol Exp Ther 349:279\u2013287. https:\/\/doi.org\/10.1124\/jpet.113.212316","journal-title":"J Pharmacol Exp Ther"},{"key":"3063_CR14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/liv.12644","volume":"35","author":"T Li","year":"2015","unstructured":"Li T, Dong ZR, Guo ZY et al (2015) Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR\/Akt\/IkappaBbeta\/NF-kappaB pathway. Liver Int 35:1416\u20131429. https:\/\/doi.org\/10.1111\/liv.12644","journal-title":"Liver Int"},{"key":"3063_CR15","doi-asserted-by":"publisher","first-page":"1776060","DOI":"10.1080\/2162402X.2020.1776060","volume":"9","author":"W Zhong","year":"2020","unstructured":"Zhong W, Wang B, Yu H et al (2020) Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. Oncoimmunology 9:1776060. https:\/\/doi.org\/10.1080\/2162402X.2020.1776060","journal-title":"Oncoimmunology"},{"key":"3063_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/2326-6066.CIR-15-0176","volume":"4","author":"AJ Vandeveer","year":"2016","unstructured":"Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW (2016) Systemic Immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an Anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol Res 4:452\u2013462. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0176","journal-title":"Cancer Immunol Res"},{"key":"3063_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot C, Rentsch CA, Gsponer JR et al (2012) Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 4:137\u2013172. https:\/\/doi.org\/10.1126\/scitranslmed.3003586","journal-title":"Sci Transl Med"},{"key":"3063_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective. Nat Rev Urol 11:153\u2013162. https:\/\/doi.org\/10.1038\/nrurol.2014.15","journal-title":"Nat Rev Urol"},{"key":"3063_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/357591","volume":"2010","author":"Y Luo","year":"2010","unstructured":"Luo Y, Knudson MJ (2010) Mycobacterium bovis bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol 2010:357591. https:\/\/doi.org\/10.1155\/2010\/357591","journal-title":"Clin Dev Immunol"},{"key":"3063_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.urolonc.2013.10.012","volume":"32","author":"L Lima","year":"2014","unstructured":"Lima L, Oliveira D, Tavares A, Amaro T, Cruz R, Oliveira MJ, Ferreira JA, Santos L (2014) The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol Oncol 32:449\u2013457. https:\/\/doi.org\/10.1016\/j.urolonc.2013.10.012","journal-title":"Urol Oncol"},{"key":"3063_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.eururo.2009.01.040","volume":"55","author":"C Ayari","year":"2009","unstructured":"Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Tetu B, Lacombe L, Fradet Y (2009) Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy. Eur Urol 55:1386\u20131395. https:\/\/doi.org\/10.1016\/j.eururo.2009.01.040","journal-title":"Eur Urol"},{"key":"3063_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/0008-5472.CAN-13-1196","volume":"74","author":"D Laoui","year":"2014","unstructured":"Laoui D, Van Overmeire E, Di Conza G et al (2014) Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res 74:24\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1196","journal-title":"Cancer Res"},{"issue":"773\u2013786","key":"3063_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.018","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, Lee Y, Li Y et al (2018) Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T cells. Immunity 48(773\u2013786):e775. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.018","journal-title":"Immunity"},{"key":"3063_CR24","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-09-1114","volume":"69","author":"DA Zaharoff","year":"2009","unstructured":"Zaharoff DA, Hoffman BS, Hooper HB et al (2009) Intravesical immunotherapy of superficial bladder cancer with chitosan\/interleukin-12. Cancer Res 69:6192\u20136199. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1114","journal-title":"Cancer Res"},{"key":"3063_CR25","doi-asserted-by":"publisher","first-page":"18627","DOI":"10.1073\/pnas.2004421117","volume":"117","author":"AC Antonelli","year":"2020","unstructured":"Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G (2020) Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma signaling. Proc Natl Acad Sci U S A 117:18627\u201318637. https:\/\/doi.org\/10.1073\/pnas.2004421117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3063_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1158\/2326-6066.CIR-18-0671","volume":"7","author":"S Domingos-Pereira","year":"2019","unstructured":"Domingos-Pereira S, Sathiyanadan K, La Rosa S et al (2019) Intravesical Ty21a vaccine promotes dendritic cells and T cell-mediated tumor regression in the MB49 bladder cancer model. Cancer Immunol Res 7:621\u2013629. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0671","journal-title":"Cancer Immunol Res"},{"key":"3063_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00481-1","author":"N Lobo","year":"2021","unstructured":"Lobo N, Brooks NA, Zlotta AR et al (2021) 100 years of bacillus calmette-guerin immunotherapy: from cattle to COVID-19. Nat Rev Urol. https:\/\/doi.org\/10.1038\/s41585-021-00481-1","journal-title":"Nat Rev Urol"},{"key":"3063_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3348","author":"A Cachot","year":"2021","unstructured":"Cachot A, Bilous M, Liu YC et al (2021) Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.abe3348","journal-title":"Sci Adv"},{"issue":"1612\u20131625","key":"3063_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.017","volume":"181","author":"DY Oh","year":"2020","unstructured":"Oh DY, Kwek SS, Raju SS et al (2020) Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181(1612\u20131625):e1613. https:\/\/doi.org\/10.1016\/j.cell.2020.05.017","journal-title":"Cell"},{"key":"3063_CR30","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","volume":"5","author":"M Kates","year":"2017","unstructured":"Kates M, Nirschl T, Sopko NA et al (2017) Intravesical BCG induces CD4(+) T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res 5:594\u2013603. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0267","journal-title":"Cancer Immunol Res"},{"key":"3063_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","volume":"49","author":"M Guilliams","year":"2018","unstructured":"Guilliams M, Mildner A, Yona S (2018) Developmental and functional heterogeneity of monocytes. Immunity 49:595\u2013613. https:\/\/doi.org\/10.1016\/j.immuni.2018.10.005","journal-title":"Immunity"},{"key":"3063_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 19:369\u2013382. https:\/\/doi.org\/10.1038\/s41577-019-0127-6","journal-title":"Nat Rev Immunol"},{"key":"3063_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coi.2017.01.002","volume":"45","author":"F Veglia","year":"2017","unstructured":"Veglia F, Gabrilovich DI (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43\u201351. https:\/\/doi.org\/10.1016\/j.coi.2017.01.002","journal-title":"Curr Opin Immunol"},{"key":"3063_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13:739\u2013752. https:\/\/doi.org\/10.1038\/nrc3581","journal-title":"Nat Rev Cancer"},{"key":"3063_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37:208\u2013220. https:\/\/doi.org\/10.1016\/j.it.2016.01.004","journal-title":"Trends Immunol"},{"key":"3063_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","volume":"61","author":"TC Zuiverloon","year":"2012","unstructured":"Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH, Zwarthoff EC (2012) Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61:128\u2013145. https:\/\/doi.org\/10.1016\/j.eururo.2011.09.026","journal-title":"Eur Urol"},{"key":"3063_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","volume":"69","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras Gonzalez GM, Anderson R, Grossman HB, Prat F, Dinney CP (2016) Cytokine Panel for response to intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-guerin. Eur Urol 69:197\u2013200. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.023","journal-title":"Eur Urol"},{"issue":"515\u2013528","key":"3063_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT et al (2018) Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173(515\u2013528):e517. https:\/\/doi.org\/10.1016\/j.cell.2018.03.017","journal-title":"Cell"},{"key":"3063_CR39","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED (2007) PD-L1 (B7\u2013H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109:1499\u20131505. https:\/\/doi.org\/10.1002\/cncr.22588","journal-title":"Cancer"},{"key":"3063_CR40","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1089\/end.2007.0298","volume":"22","author":"J Huang","year":"2008","unstructured":"Huang J, Lin T, Xu K et al (2008) Laparoscopic radical cystectomy with orthotopic ileal neobladder: a report of 85 cases. J Endourol 22:939\u2013946. https:\/\/doi.org\/10.1089\/end.2007.0298","journal-title":"J Endourol"},{"key":"3063_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrc3858","volume":"15","author":"T Kobayashi","year":"2015","unstructured":"Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C (2015) Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer 15:42\u201354. https:\/\/doi.org\/10.1038\/nrc3858","journal-title":"Nat Rev Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03063-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03063-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03063-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T02:05:33Z","timestamp":1653098733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03063-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03063-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was provided by the Committees for Ethical Review of Research at Sun Yat-sen University and was performed according to the institutional ethical guidelines for animal experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}